New Therapies of Liver Diseases

In this Special Issue of the journal, advancements in the treatment of liver diseases are illustrated by international experts in the field. New treatment options for primary biliary cirrhosis and, hopefully, primary sclerosing cholangitis are discussed. Up-to-date pharmacological therapy for preven...

Descripción completa

Detalles Bibliográficos
Otros Autores:	Toniutto, Pierluigi (Editor)
Formato:	Libro electrónico
Idioma:	Inglés
Publicado:	Basel MDPI - Multidisciplinary Digital Publishing Institute 2022
Materias:	Public health & preventive medicine tolvaptan cirrhotic ascites survival rate furosemide primary biliary cholangitis autoantibodies ursodeoxycholic acid treatment response second line therapy primary biliary cholangitis (PBC) primary sclerosing cholangitis (PSC) clinical trials ursodeoxycholic acid (UDCA) Farnesoid X Receptor (FXR) agonist Pan-Peroxisome Proliferator-Activated Receptor (PPAR) agonists liver cancer systemic treatment immunotherapy real-world unresectable hepatocellular carcinoma cirrhosis decompensation bleeding varices survival infection alcoholic hepatitis acute-on-chronic liver failure cholangiocarcinoma colorectal cancer metastases hepatocellular carcinoma liver transplantation Milan criteria alpha-fetoprotein solid organ transplantation liver injury immunosuppressant SARS-CoV-2 humoral response vaccination portal-systemic shunt ammonia vigilance HBV HDV antivirals functional cure pharmacology acute-on-chronic liver failure (ACLF) liver transplantation (LT) decompensated cirrhosis portal hypertension ascites non-selective beta-blockers TIPS rifaximin human albumin statins targeted therapy effective hypovolemia anti-mineralocorticoids loop diuretics vaptans
Ver en Biblioteca Universitat Ramon Llull:	https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009660398306719